Novo Nordisk Shares Drop Over 7% as New Targets Fail to Reassure Investors
Shares of Novo Nordisk (NYSE:NVO) fell over 7% on Monday after the Danish drugmaker announced new long-term targets that failed to alleviate investor concerns about competition in the weight-loss drug market. The company outlined plans for more than five multi-blockbuster drugs by 2030 and $23 billion in risk-adjusted pipeline sales by 2035, but investors remained worried over patent expirations of its key product semaglutide in major markets like the U.S., where it accounts for over half of Novo's revenue. CEO Mike Doustdar acknowledged these concerns during a Capital Markets Day event and emphasized the need to diversify as exclusivity wanes. Investor anxiety was further heightened by mixed results from an experimental drug, CagriSema, which delivered 23% weight loss in Phase 3 trials—slightly below Eli Lilly's tirzepatide at 25.5%. The company currently holds about 39% of the obesity drug market compared to Eli Lilly’s 61%, and semaglutide accounts for roughly 75% of Novo's sales, making it particularly vulnerable as key patents expire in major markets from 2030 onward.
Topics: clinical trial results competition patent expiration pharmaceuticals stock decline